Spontaneously arising tumor cells are not usually angiogenic at first. The phenotypic switch to angiogenesis is usually accomplished by a substet that induces new capillaries that then converge toward the tumor. The switch clearly involves more than simple upregulation of angiogenic activity and is thought to be the result of a net balance of positive and negative regulators. Tumor growth is although to require disruption of this balance and hence this switch must turned on for cancer progression. Progenitor endothelial cells, the crosstalk between angiogenic factors and their receptors and the interaction between vasculogenesis and lymphangiogenesis are all factors that may contribute to the switch. Its promotion is also the outcome of genetic instability resulting in the emergence of tumor cell lines. This review describes the history of the angiogenic switch illustrated in the literature and with particular reference to the three transgenic mouse models, namely RIP1-TAG2, keratin-14 (K14) (human papilloma virus) HPV16 and papilloma virus, used for stage-specific assessment of the effects of antiangiogenic and antitumorigenic agents.
Introduction
The current wisdom is that both solid and hematological tumors are endowed with angiogenic capability and that their growth, invasion and metastasis are angiogenesis-dependent.
1 Judah Folkman, a highly rated pioneer and researcher in this field wrote: 'Once tumor take has occurred, early increase in tumor cell population must be preceded by an increase in new capillaries that converge upon the tumor'. 2 Solid and hematological tumors are endowed with angiogenic capability and their growth, invasion and metastasis are angiogenesis-dependent.
Neoplastic cell populations can only form a clinically observable tumor if the host produces a vascular network sufficient to sustain their growth. Furthermore, new blood vessels provide them with a gateway through which to enter the circulation and metastasize distant sites.
Studies on neoplastic transformation have focused on events that occur within transformed cells. They have addressed the microenvironment of tumor cells and documented its importance in supporting tumor progression. The pathogenesis of most cancers, in fact, includes complex and mutual interactions that affect the number and phenotype of the tumor cells and various normal stromal cells. The intricate tumor-microenvironmental interactions are increasingly recognized as critical features of several neoplasias. Tumor cells are surrounded by an infiltrate of inflammatory cells, namely lymphocytes, neutrophils, macrophages and mast cells, which communicate via a complex network of intercellular signaling pathways, mediated by surface adhesion molecules, cytokines and their receptors.
How do tumor cells switch to the angiogenic phenotype?
Spontaneously arising tumor cells are not usually angiogenic at first. 3 The phenotypic switch to angiogenesis is usually accomplished by a subset that induces new capillaries which then converge toward the tumor. These new vessels perfuse the tumor with blood, which transports nutrients and oxygen to the tumor and catabolities away from it, and their endothelial cells produce a spectrum of growth factors with a paracrine stimulatory effect on the tumor cells and a variety of matrixdegrading proteinases that facilitate invasion. 4 An expanding endothelial surface also gives tumor cells more opportunities to enter the circulation and metastasize, while their release of antiangiogenic factors explains the control exerted by primary tumors over metastasis. These observations suggest that tumor angiogenesis is linked to a switch in the equilibrium between positive and negative regulators. In normal tissues, vascular quiescence is maintained by the dominant influence of endogenous angiogenesis inhibitors over angiogenic stimuli. Tumor angiogenesis, on the other hand, is induced by increased secretion of angiogenic factors and/or downregulation of such inhibitors.
Neovascular channels allow tumor cells to metastasize hematogenously. For example, 10-100 million endothelial cells are required to support the smallest palpable breast cancer. This is one centimeter in diameter, weighs one gram and consists of approximately one billion cancer cells. 5 It sheds 2 Â 10 6 cancer cells into the systemic circulation every 24 h. 6 Of these, only one survives. It lodges in a distant organ as a micrometastasis and remain quiescent until the angiogenesis occurs in its site.
Most human tumors arise and remain in situ without angiogenesis for months to years before switching to an angiogenic phenotype, though the preneoplastic stage of breast and cervical carcinomas becomes neovascularized before the malignant tumor appears. In the 1970s, Gullino et al. observed that the resting adult rodent mammary gland has limited, if any angiogenic capacity, whereas this is consistently acquired by mammary carcinomas. Lesions with a high frequency of neoplastic transformation induce angiogenesis at a much higher rate than those with a low frequency. This elevated angiogenic capacity was observed long before any morphological sign of neoplastic transformation. [7] [8] [9] [10] Hyperplastic human mammary gland lesions behave in the same way. 9 Angiogenesis may thus be an early marker of neoplastic transformation.
In human primary tumors, microscopic areas of intense angiogenesis flank less vascularized areas, 11 suggesting a heterogeneity of clones of highly angiogenic cells as well as weakly angiogenic or nonangiogenic clones. In cervical neoplasia, a switch is readily apparent in mid-late dysplasias, wherein new vessels became densely apposed along the basement membrane underlying the dysplastic epithelium. 12 The role of progenitor cells in tumor angiogenesis
The tumor blood supply can expand by incorporation of bone marrow progenitor cells into existing vessels. The magnitide of this contribution to endothelial cells of tumor vessels is still unclear. Bone marrow-derived stem cells may be a source of endothelial precursor cells (EPC) recruited for tumor-induced neovascularization. It has been assumed that the additional endothelial cells required to construct new tumor vessels come from the division and proliferation of local endothelial cells. Endothelial cells incorporated into sites of neovascularization, including tumor-induced new blood vessels, may be derived from these precursor cells.
Recruitment of EPC to tumor angiogenesis takes place in five steps: (a) active arrest and homing of the circulating cells within the angiogenic microvasculature; (b) transendothelial extravasation into the interstitial space; (c) extravascular formation of cellular clusters and (d) creation of vascular sprouts and cellular networks; (e) incorporation into a functional microvasculature.
As the first step, certain values in the blood, for example, high vascular endothelial growth factor (VEGF), favor and enhance differentiation of hematopoietic stem cells toward the EPC lineage. 13, 14 High levels of VEGF produced by tumors may mobilize bone marrow-derived stem cells in the peripheral circulation and enhance their recruitment into the tumor vasculature. 15, 16 Moreover, Hattori et al. 16 showed that combined elevation of VEGF and angiopoietin-1 (Ang-1) remodels of the bone architecture, with depletion of the sinusoidal spaces of hematopoietic cells and a parallel increase in bone marrow vascularization and splenomegaly.
Hypoxia also mobilize EPC from the bone marrow in the same way as hematopoietic cytokines, such as granulocyte-macrophage colony stimulating factor (GM-CSF). 13 Malignant tumor growth results in neoplastic tissue hypoxia, and may mobilize bone marrow-derived endothelial cells in a paracrine fashion and thus contribute to the sprouting of new tumor vessels.
Lyden et al. 17 demonstrated that transplantation and engrafment of b-galactosidase-positive wild-type bone marrow or VEGF-mobilized stem cells into lethally irradiated Id-mutant mice is sufficient to reconstitute tumor angiogenesis. In contrast to wild-type mice, Id-mutants fail to support the growth of tumors because of impaired angiogenesis. Tumor analysis demonstrates the uptake of bone marrow-derived VEGF receptor-2 (VEGFR-2) þ EPC into vessels surrounded by VEGFR-1 þ myeloid cells. Defective angiogenesis in Id-mutant mice is associated with impaired VEGF-induced mobilization and proliferation of the bone marrow precursor cells. Inhibition of both VEGFR-1 and VEGFR-2 signaling is needed to block tumor angiogenesis and induce necrosis.
Reyes et al. 18 found that multipotent adult progenitor cells (MAPC) respond to angiogenic stimuli by migrating to tumor sites and contributing to tumor vascularization. They also found that in vivo angiogenic stimuli in a tumor microenvironment are sufficient to recruit MAPC to the tumor bed and induce their differentiation into endothelial cells that contribute to the tumor vasculature.
Vajkoczy et al. 19 propose the term 'angiomorphosis' as the process of enhancing tissue vascularization through: (a) active recruitment of EPC from the circulation by endothelial cells and (b) the action of EPC as organizers of the angiogenic process.
The crosstalk between the different angiogenic factors and their receptors in tumor angiogenesis and progression All the VEGF isoforms share common tyrosine-kinase receptors, VEGFR-1 (or Flt-1), VEGFR-2 (or KDR/Flk-1), VEGFR-3 (or Flt-4). VEGF-A binds with high affinity VEGFR-1 and -2 and plays an essential role in vasculogenesis and angiogenesis. 20 It has also been shown to induce lymphangiogenesis through VEGFR-2. VEGF-B overlaps VEGF-A activities by activating VEGFR-1. 21 VEGF-C and VEGF-D are both angiogenic via VEGFR-2 and VEGFR-3, and lymphangiogenic (primarily VEGF-D) via VEGFR-3. 22, 23 The absolute and relative expression levels of VEGFR-2 and VEGFR-3 in endothelium may determine whether VEGF-C/ D elicits angiogenic or lymphangiogenic effects. Strict demarcation of the effects of VEGFR-2 and VEGFR-3 activation in terms of angiogenesis and lymphangiogenesis is complicated by observations that VEGFR-3 is involved in maintenance of tumor blood vessels in a mouse model 24 and in human tumors, 25, 26 and the detection of VEGFR-2 expression on lymphatic endothelial cells. 27, 28 A nonkinase receptor, neuropilin-1 (NP-1), initially shown to mediate guidance of neurite growth, acts as a high affinity coreceptor. It enhances the binding of VEGF-A to VEGFR-2 and is expressed on the surface of endothelial and tumor cells. 29 Ang-1 and Ang-2 are secreted factors that mediate their effects by binding to the endothelial-specific Tie-2 receptor tyrosine kinase. 30 In vivo analysis has revealed that Ang-1 recruits periendothelial cells, whereas Ang-2 is presumed to destabilize blood vessels by interfering with constitutive Ang-1/Tie-2 signals in the vessel wall, leading to detachment of the perivascular cells and allowing the vessel endothelium to revert to a more plastic state of angiogenesis. 31, 32 Apparently conflicting publications report increased, decreased or unchanged expression levels of both Ang-1 and Ang-2 in a wide range of tumors. 33 Although absolute levels of either Angs may increase or decrease, the ratio Ang-1:Ang-2 shift in favor of Ang-2. This implicates Ang-2 as a candidate for the angiogenic switch and also a potential therapeutic target.
The interaction between vasculogenesis and lymphangiogenesis
It is generally accepted that vasculogenesis is limited to early embryogenesis and is believed not to occur in the adult, whereas angiogenesis occurs in both the developing embryo and postnatal life. However, the distinction between them is not absolute, because both require endothelial cell proliferation and migration and three-dimensional reorganization of newly formed blood vessels, nor are they mutually exclusive, inasmuch as angioblasts can be incorporated into expanding pre-existing blood vessels. 34 Recent observations indicate that vasculogenesis may not be restricted to early embryogenesis, but may also have a physiological role or contribute to the pathology of vascular diseases in adults and suggest that postnatal vasculogenesis also contribute to tumor neovascularization. 35 Cancer cells escape from tumor via two primary routes, blood and lymphatic vessels, to establish distant metastases. Although
The history of the angiogenic switch concept D Ribatti et al the metastatic dissemination of tumor cells to regional lymph nodes is a common feature of many human cancers, it is not clear how tumor cells enter the lymphatic system, nor whether tumors utilize existing lymphatic channels or their dissemination requires the de novo formation of lymphatics (lymphangiogenesis) 36, 37 VEGF-C and VEGF-D have been identified as specific lymphangiogenic factors, which bind to and induce tyrosine phosphorylation of VEGFR-3. 28 A correlation between VEGF-C and VEGF-D expression, tumor lymphangiogenesis and the formation of metastases in regional lymph nodes has been described in a range of human tumors, including malignant melanoma and lung, breast, colrectal and gastric carcinomas. 38 Although these findings provide no information on the mechanism of tumor cell dissemination, they raise the possibility that VEGF-C and VEGF-D may increase metastasis by increasing the number and size of lymphatic vessels, or alternatively by altering the functional properties of existing lymphatics.
Lymphangiogenesis stimulators, such as VEGF-C and VEGF-D can be produced and secreted by tumor cells, stromal cells or macrophages. Proteolysis converts them into their mature forms that bind both, VEGFR-2 and VEGFR-3 on the surface of lymphatic endothelial cells with high affinity. The 'lymphangiogenic-switch', by changing tumors with absent lymph vessels into tumors with lymph vessels renders lymphatic metastasis possible.
The significance of these models in testing antiangiogenic compounds
The finding that circulating bone marrow-derived EPC are recruited to tumor neovasculature provides an additional rationale for using bone marrow stem cells as the target in an antiangiogenic gene therapy-mediated anticancer strategy. As these gene-modified EPC are recruited by tumor-elaborated factors, a higher local milieu of angiogenesis inhibitors is probably established at the target sites. Davidoff et al. 39 modified murine bone marrow-derived cells with a gene encoding an angiogenesis inhibitor, a soluble, truncated form of the VEGFR-2 (tsFlk-1) together with green fluorescent protein (GFP) or GFP alone. Tumor growth in mice challenged 3 months after transplantation with tsFlk-1 expressing bone marrow cells was significantly inhibited compared with transplanted controls. Immunohistochemical analysis of tumors in each group demonstrated colocalization of GFP expression in cells stained with endothelial cell markers, suggesting that endothelial cells of the tumor-induced neovasculature were derived, at least in part, from bone marrow precursors. Quantitation of EPC in the peripheral blood may offer a potential surrogate marker for monitoring the correct administration and subsequent efficacy of antiangiogenic therapies.
The VEGF signaling pathway can be inhibited at various levels, that is, by blocking the VEGF activity with monoclonal antibodies, 40 blocking the VEGFR with specific inhibitors 41 or interfering with the tyrosine-kinases activated by the VEGF/ VEGFR interaction. 42 Systemically administered antibodies to VEGF-A accumulate selectively in tumor vessels in much higher concentrations than in normal tissue. 43 These antibodies and those that block VEGFR retard tumor growth and reduce tumor size in mice. 44, 45 The latest antibodies selectively recognize the complex that VEGF-A forms with VEGFR-2 on vascular endothelium. 46 Preclinical studies with VEGF-neutralizing antibodies had shown that inhibition of VEGF inhibits matrix metalloproteinase (MMP) production and induction of apoptosis in cells expressing VEGFR, 47 suppresses the production of tumor necrosis factor alpha (TNF-a), and interleukin-1 alpha (IL-1a) in bone marrow stromal cells. A humanized murine anti-VEGF monoclonal antibody, Bevacizumab (Avastin), which recognizes all VEGF-A isoforms without crossreacting with other growth factors, has displayed potent antitumor activity in experimental models. 48 Clinical trials with Avastin showed that in patients with metastatic colorectal cancer there was a significant survival benefit when combined with chemotherapy. 49 Another antiangiogenic target is the blockade of VEGFR or the tyrosine-kinase proteins involved in signal transduction. Receptor tyrosine kinase (RTK) and their ligands have emerged as critical molecular regulators of angiogenesis. These agents directly block aberrant mitogenic growth factor signaling in both transformed and nontransformed cells. Small selective nonimmunogenic synthetic molecules have displayed specific activity associated with an acceptable toxicity profile and good resistance to enzyme lysis. 50 VEGFR are expressed in some human cancers, including colon cancer, 51 thus raising the possibility that anti-VEGF therapies may simultaneously target endothelial and tumor cells in this subset of cancers.
Antilymphangiogenesis has been established in animals by using antibodies against VEGF-C and VEGF-D. 52, 53 As a result, lymphatic metastasis was prevented. Another possibility for inhibition of lymphangiogenesis is the blocking of VEGFR-3 by antibodies or thyrosine kinase inhibitors. 54 However, the efficacy of antilymphangiogenesis is controversial because destruction of lymph vessels could augment interstitial pressure in the tumor and thus increase hematogeneous metastasis. 55 The concept of angiogenic switch
The angiogenic switch whereby the normally quiescent vasculature grows new capillaries separates the avascular (prevascular) phase characterized by a dormant tumor and the vascular phase in which exponential tumor growth ensues. In the prevascular phase, tumor cells proliferate (sometimes as rapidly as in the vascularized tumor), but the rate of tumor cell death (apoptosis) counterbalances this proliferation and maintains the tumor mass in a steady state. Dormant tumors have been discovered during autopsies of individuals who died of causes other causes. 56 Activation of the switch itself has been attributed to the synthesis or release of angiogenic factors. The balance hypothesis 57, 58 assumes that the level of angiogenesis inducers and inhibitors governs cell differentiation states of quiescence or angiogenesis. This balance is altered by increasing activator gene expression, changing the bioavailability or activity of the inducer proteins, or reducing the concentrations of endogenous angiogenesis inhibitors, here, too, via changes in gene expression or processing/bioavailability.
Factors involved in the angiogenic switch
The switch depends on increased production of one or more of the positive regulators of angiogenesis, such as VEGF, fibroblast growth factor-2 (FGF-2), IL-8, transforming growth factor beta (TGF-b), platelet derived growth factor (PDGF), pleiotrophins and others. These can be exported from tumor cells, 59 mobilized from the extracellular matrix 60 or released from host cells (e.g. macrophages) recruited to the tumor. 61 Expression of
The history of the angiogenic switch concept D Ribatti et al endogenous inhibitors, such as thrombospondin-1 (TSP-1) or interferon beta may be downregulated. [62] [63] [64] [65] Thus, the switch clearly involves more than simple upregulation of angiogenic activity and has thus been seen as the result of a net balance of positive and negative regulators.
Integrin signaling also contributes to this regulatory balance. Quiescent vessels express one class of integrins, whereas sprouting capillaries express another. Interference with signaling by the latter class of integrins can inhibit angiogenesis. 66 In vivo screening of phage libraries in murine models has identified specific motifs, including RGD, GSL, and NGR, that bind to integrins anb3, anb5 and a5b1, matrix metalloproteases (MMPs) and VEGFR that are upregulated in neoangiogenic tumor endothelial cells. 67, 68 Proteases control the bioavailability of angiogenic activators and inhibitors. Some release FGF-2 stored in the extracellular matrix, 69 whereas plasmin, a proangiogenic component of the clotting system, cleaves itself into an angiogenesis inhibitor form, namely angiostatin. 70 Nutrient deprivation modulates gene expression and may also contribute to the activation of the angiogenic process. Glucose deprivation-induced oxidative stress activates the expression or release of angiogenic growth factors. 71 What is the evidence that genetic instability must promote the angiogenic switch?
A widely accepted view is that the progression of tumors reflects their genetic instability, this being defined as their higher mutation rate compared with normal tissues due to corruptions in checkpoint genes are crucial for genome replication. 72 Progression is thus achieved through the accumulation of multiple lesions that impair the control of cell proliferation and survival and thereby shape the complex phenotype of tumor cells. 73 Genetic instability may be required for the emergence of angiogenic tumor cell lines that enhance a tumor's growth and malignancy. In the absence of such instability, these lines cannot grow, even if the relevant mutations are generated at low levels because the angiogenic promoters will not sufficient to counter the influence of inhibitory factors. Inhibition of angiogenesis can thus be viewed as a host defense and a tumor must be genetically unstable to be able to exceed a certain size. Genetic control of the physiological levels of endogenous angiogenesis inhibitors may well be a line of defence against the conversion of dormant tumor cells to a malignant phenotype.
Genetic instability must therefore act upstream and promote the angiogenic switch. Evidence in favor of this view has been recently acquired from reversible transgene models and multigene-transformed cells. Watnick et al. 74 observed that the switch in a cell transformation model was dependent on oncogenic RAS expression. They showed that low expression levels induced cell transformation and increased VEGF expression, and that further increases in the abundance of the oncogene led to repression of the antiangiogenic factor TSP-1 through Myc activation, and subsequent tumor expansion. Expression of the SV40 early region, TERT and activated RAS were sufficient to transform primary epithelial cells in vitro. 75 However, their ability to grow in vivo depended on the level of HRAS expression: cells that expressed low levels were dormant and nonangiogenic, whereas those that expressed high levels progressed to full-blown tumors. VEGF-A levels increased only modestly (1.4-fold) in tumors expressing high RAS levels, whereas TSP1 levels increased eightfold. Tumor formation from cells that expressed low RAS levels was indicated by simple overexpression of VEGF-A. This shows tumor progression was blocked because the angiogenic switch was not activated. It also supports the view that the switch is determined by the balance between pro-and antiangiogenic factors, and that oncogene expression can influence this balance.
BHK 21/cl 13 cells, an immortal but nontumorigenic line of hamster fibroblasts, were converted to malignancy and anchorage independence by loss of a functioning tumor-suppressor gene. These cells were highly tumorigenic in nude mice and neonatal hamsters, and potently angiogenic in vivo. Normal BHK cells and suppressed hybrids generated by fusing transformed BHK cells with either nontransformed BHK or normal human fibroblasts were unable to induce angiogenesis when they or their concentrated conditioned media were introduced into rat corneas, whereas transformed BHK cells and transformed segregants from the suppressed hybrids were angiogenic. Mixing experiments showed that normal cells elaborated an angiogenesis inhibitor whose production was blocked coincidentally with suppressor loss. When endothelial cell chemotaxis was used as an in vitro corollary of angiogenesis in the rat cornea assay, the inhibitor was purified and shown to be TSP-1. 65 This was the first illustration of a new function for a tumor-suppressor gene, namely regulation of the production of a naturally occurring inhibitor of angiogenesis. In another set of experiments, Dameron et al. 75 established a direct link between the p53 tumor-suppressor gene, tumor angiogenesis and TSP-1. To examine the effect of p53, they used cultured fibroblasts from patients with the Li-Fraumeni syndrome who have inherited one wild-type allele and one mutant allele of the p53 gene. When the wild-type allele was lost, these cells acquired potent angiogenic activity coincidental with loss of TSP-1 production. Transfection revealed that p53 stimulated the endogenous TSP-1 gene and positively regulated the TSP-1 promoter sequences.
The RIP1-TAG2 model
The mechanism of the switch was first described in 1985 by Hanahan 76 who developed transgenic mice in which the large T oncogene is hybridized to the insulin promoter. In this islet cell tumorigenesis (RIP1-TAG2 model), these mice express the large T antigen (TAG) in all their islet cells at birth, and express the SV40 TAG under the control of the insulin gene promoter, which elicits the sequential development of tumors in the islets over a period of 12-14 weeks. Tumor development proceeds by stages during which about half the 400 islets become hyperproliferate, while a subset (about 25%) subsequently acquire the ability to switch to angiogenesis.
3 Some 15-20% of these angiogenic islets develop into benign tumors, encapsulated lesions and invasive carcinomas. 77 This multistage pathway suggests the sequential involvement of multiple ratelimiting genetic and epigenetic events in the progression from normal cells to tumors. The b-cells become hyperplastic and progress to tumors via a reproducible and predictable multistep process. 76 One step occurs at 6-7 weeks, when angiogenesis is switched on in approximately 10% of preneoplastic islets. Solid vascularized tumors first appear at 9-10 weeks, initially as small nodules that grow and progress to large islet tumors, with welldefined margins, as well as two classes of invasive carcinoma. 77 Lopez and Hanahan identified stage-specific molecular markers accessible via the circulation, either on the surface of endothelial cells, their periendothelial support cells (pericytes and smooth muscle cells) or even tumor cells themselves (as a result of the hemorrhagic leaky angiogenic vasculature). They selected phage pools that homed preferentially to different
The history of the angiogenic switch concept D Ribatti et al stages during RIP1-TAG2 tumorigenesis. In addition to 'panangiogenic' markers shared by many types of tumors, they identified vascular target molecules characteristic of this tumor's tissue of origin and not expressed in the vessels of several tumor types growing in or under the skin.
Angiogenic islets are revealed both morphologically in tissue sections and in isolated islets by their red color and microhemorrhagic islands, and functionally by their ability to elicit endothelial cell migration, proliferation and tube formation in an in vitro collagen bioassay involving coculture of dispersed capillary endothelial cells and isolated islets. 3 This onset pattern closely resembles that of angiogenesis in human tumors.
Two concepts emerged from this early characterization of tumorigenesis in RIP-TAG transgenic mice: (a) the existence of distinct stages of premalignant progression, namely a hyperplastic stage followed by a stochastic angiogenic stage and (b) the development of angiogenesis well before the emergence of an invasive malignancy. The temporal and histological changes that occur in the RIP-TAG model are consistent with the multistep paradigm for tumorigenesis of human cancers. 78 The high incidence of occult human cancers suggests that this angiogenic switch may, as in the RIP-TAG model, be a relatively late event that plays a significant role in the transition from microscopic foci to macroscopic tumor. 79 These data suggested that induction of angiogenesis during multistage carcinogenesis is coordinated by an 'angiogenic switch'. VEGF signaling is primarily implicated in angiogenesis and tumorigenesis in RIP1-TAG2 mice. The islets are extensively vascularized to facilitate their monitoring of serum glucose levels and hence the secretion of insulin and other hormones for endocrine regulation of carbohydrate metabolism. VEGF-A, VEGF-B and VEGF-C are all expressed in normal islet b-cells.
80
VEGF-A is expressed at all stages of RIP1-TAG2 tumorigenesis. 80 Such constancy suggests that if VEGF-A activity is important in this tumorigenesis pathway, other modes of regulation may be involved. Inoue et al. 81 showed that five VEGF ligand genes are expressed in normal islets and throughout tumorigenesis. Moreover, they produced a beta-cell-specific VEGF-A knockout that resulted in islets with reduced vascularity, but essentially normal physiology. In RIP1-TAG2 mice where most oncogeneexpressing cells had deleted the VEGF-A gene, both angiogenic switching and tumor growth were severely disrupted, as was the neovasculature.
Overexpression of VEGF-C in beta cells via a RIP-VEGF-C transgene induces periislet lymphatic vessels, but has no discernable effect on intraislet blood vessels. 82 Extensive lymphatic channel formation, in fact, was observed around (but not within) 98% of islets from RIP-VEGF-C transgenic mice, that is, the anatomical units in which the transgene is expressed. VEGF-C overexpression did not increase intratumoral vascularity or enhance tumor growth, though peritumoral lymphatic vessels it induced facilitated metastases to the draining mesenteric lymph nodes. 82 To assess the role of VEGF-Cinduced lymphangiogenesis in tumor metastasis, Mandriota et al. 82 crossed RIP-VEGF-C mice with RIP1-TAG2 mice. b-Cell tumors in RIP1-TAG2 mice invade locally, but are not metastatic. VEGF-C expression in double transgenics resulted in the de novo formation of lymphatics in intimate association with b-cell tumors associated with the formation of metastases in the draining regional mesenteric lymph nodes in 37% of mice.
Mice genetically deficient in platelet derived growth factor beta (PDGFB) or its receptors have blood vessels with loose pericyte attachment, irregular vessel caliber, luminal projections of endothelial cells and hemorrhage. 83 Similar abnormalities occur in many tumor vessels.
Bergers et al. 84 demonstrated that MMP-9 plays a crucial role in the initial angiogenic switch during islet carcinogenesis and proposal mobilization of VEGF from an extracellular reservoir as its mode of action. Giraudo et al. 85 used the keratin-14 (K14)-human papilloma virus (HPV) 16 transgenic tumor model to demonstrate MMP-9 in the tumor stroma concomitant with the angiogenic switch, expressed by infiltrating macrophages. Moreover, preclinical trials targeting MMP-9 and angiogenesis with a MMP inhibitor and with a bisphosponate, zoledronic acid, showed that both were antiangiogenic. Other enzymes are involved in islet tumorigenesis. Joyce et al. 86 have shown that a subset of papain family Clan CA proteases known as cathepsins make an important contribution to the development of islet tumors and are upregulated during their progression. Cathepsin activity was assessed with chemical probes to allow biochemical and in vivo imaging. Increased activity was associated with the angiogenic vasculature and invasive fronts of carcinomas, with differential expression in immune, endothelial and cancer cells. A broad-spectrum cysteine inhibitor that knocked out cathepsin function at different stages of tumorigenesis impaired angiogenic switching in progenitor lesions, as well as tumor growth, vascularity and invasiveness. Cysteine cathepsins are also upregulated during HPV16-induced cervical carcinomas. Joyce et al. 87 have since shown that heparanase expression increases during RIP-TAG tumorigenesis, predominantly supplied by innate immune cell infiltrating neoplastic tissues.
Joyce et al. 88 analyzed the vasculature in the angiogenic stages of RIP-TAG model islet tumorigenesis with phage libraries that display short peptides, and identified peptides that discriminate between the vasculature of the premalignant angiogenic islets and the fully developed vasculature. One peptide is homologous with PDGF-B, which is expressed in endothelial cells, while its receptor is expressed in pericytes. Three PDGF ligand genes are expressed in the tumor endothelial cells, while PDGFB receptor (PDGFB-R) is expressed in tumor pericytes. 89 The RIP-TAG transgenic mouse as a model for testing antiangiogenic agents RIP-TAG transgenic mice provides a useful model for examining the effects of various antiangiogenic and antitumorigenic agents, as it allows these compounds to be tested in a stage-specific manner. 90 In one study, they were treated with three angiogenesis inhibitors: AGM 1470 (TNP 470), alpha interferon and minocycline. 91 Therapy began at 6 weeks of age at the onset of activation of the angiogenic switch. The regimen retarded angiogenesis, increased tumor cell apoptosis, and significantly reduced tumor volume to 10% of that of control mice.
Treatment of RIP-TAG with SU5416, 92 a small molecule inhibitors of the VEGFRs, results in a significant reduction (490%) in the number of angiogenic islets and in substantially reduced tumor burden. 84 Similar results were obtained when an adenovirus vector was used to deliver a soluble form of VEGFR-1 that binds placenta growth factor (PLGF), VEGF-A and VEGF-B. 93 Casanovas et al. 94 have since used functionblocking antibodies to VEGFR-1 and VEGFR-2 to probe their roles in controlling angiogenesis in RIP-TAG model. They showed that inhibition of VEGFR-2 but not VEGFR-1, markedly disrupted angiogenic switching and initial tumor growth. In latestage tumors, phenotypic resistance to VEGFR-2 blockade
The history of the angiogenic switch concept D Ribatti et al emerged, as tumors regrew after an initial period of growth suppression. Selective PDGF-antagonists could be used to determine whether inhibition of PDGF signaling destabilizes tumor vasculature by negatively affecting pericyte survival in tumors. Pericytes were validated as therapeutic target by using kinase inhibitors selective for PDGFB-R. Pharmacological inhibition of PDGFR signaling in RIP1-TAG-2 mice disrupted pericyte association with tumor endothelium, inhibited angiogenesis, and reduced the vascularity of islet tumors. 89 Moreover, combination of PDGFR antagonists with a VEGFR-2 inhibitor greatly perturb pericyte-endothelial cell interactions and result in tumor regression. 89 Pancreatic tumors in RIP1-TAG-2 mice regressed in part by destabilization of interactions between pericytes and endothelial cells following treatment with Gleevec or SU6668. 89, 95 Recent findings have implicated PDGFB and its receptors in tumor lymphangiogenesis, 96 thus suggesting additional therapeutic applications to PDGFR inhibitors.
Brantley et al. 97 and Cheng et al. 98 reported that blocking ephrin-A (Eph-A) class receptors activation inhibits angiogenesis in RIP-TAG model. Eph-A1 ligand was expressed in both tumor and endothelial cells, and Eph-A2 receptor was localized primarily in tumor-associated vascular endothelial cells. Soluble Eph-A2-Fc or Eph-A3-Fc receptors inhibited tumor growth in vivo. These data suggest that the Eph-A signaling pathway is an attractive novel target for antiangiogenic therapy in cancer.
Joyce et al. 87 showed that PI-88, a sulfated oligosaccharide that inhibits heparanase activity, reduces the number of early angiogenic progenitor lesions and impairs tumor growth in later stages of RIP-TAG tumorigenesis.
The K14-HPV 16 transgenic tumor model
The first pattern of upregulation of angiogenesis-inducer genes is evident during epidermal squamous carcinogenesis in K14-HPV16 transgenic mice. This tumor model expresses HPV type 16 oncogene under control of the K14 promoter. These mice express the HPV16 E6 and E7 oncogenes in the basal cells of their squamous epithelia 99 in the FVB/n strain background. They spontaneously develop epidermal squamous cell cancers (SCC) in a multistage fashion. 100 Their skin appears normal at birth, but becomes hyperplastic within the first month, and focal dysplasias develop between 3 and 6 months of age. These focal dysplasias are angiogenic and by 1 year have developed into invasive SCC in about half of the mice.
In normal murine epidermis, and in 'normal' epidermis expressing the HPV16 oncogenes, neither aFGF nor VEGF are transcribed at detectable levels. Both well and moderately differentiated SCC arise from pathways beginning as hyperplasia and progressing through varying degree of dysplasia. A perceptible increase in dermal capillary density is first apparent in the first-month hyperplastic stage. There is a striking increase in both the number and distribution of dermal capillaries in the early and advanced dysplastic lesions; numerous vessels become closely apposed to the basement membrane separating dysplastic keratinocytes from the underlying stroma. The pattern is indicative of an angiogenic switch from vascular quiescence to the modest angiogenesis seen in the early, low-grade lesions, followed by a second, striking upregulation of angiogenesis in high-grade neoplasias as well as invasive cancer.
Progression is accompanied by the upregulation of proangiogenic factors, such as VEGF 101 and FGF-2, 102 and the model has called attention to the involvement of proteases from inflammatory mast cells 103 and other bone marrow-derived cells (neutrophils and macrophages) in angiogenesis and tumor progression. 104 Arbeit et al. 102 elaborated a derivative model of estrogen-induced carcinoma in female K14-HPV16 mice. Cervical carcinoma developed in several stages in 80% of these mice after 6 months of estrogen treatment.
Neither the oncogene SV40TAG used in the creation of the RIP-TAG mice, nor oncogenes E6 and E7 used in the creation of K14-HPV16 mice induced angiogenesis on their own. Additional changes during progression enable angiogenesis. All three oncogenes, in fact, bind and inactivate the tumor-suppressor gene products p53 and RB.
The papilloma virus type 1 transgenic tumor model
In another model, formation of dermal fibrosarcomas in BPV1.69 transgenic mice occurred in three histologically distinct stages (normal, mild and aggressive fibromatosis) 105 characterized by differential expression of c-jun and jun-b proto-oncogenes and their associated AP1 transcription factor activities. 106 Evaluation of microvascular density revealed a dramatic increase in capillaries in the aggressive fibromatosis stage. 59 Moreover, conditioned medium from cells derived from normal dermis and mild fibromatosis did not display endothelial cell mitogenic activity, whereas those from the aggressive fibromatosis and fibrosarcoma did. 59 FGF-2 gene expression was at a similar level in all cell lines, irrespective of the presence or absence of mitogenic activity in conditioned medium. Thus, changes in FGF-2 gene expression did not explain the angiogenic switch.
Concluding remarks
The three transgenic mouse models described here display a similar pattern of the switch to persistent angiogenesis during tumor development. Their analysis throughout multistep tumorigenesis showed that angiogenesis was activated in the midstage lesions. When taken together with the effects of angiogenesis inhibitors, these observations indicate that angiogenesis is a prerequisite for the rapid clonal expansion associated with the formation of macroscopic tumors.
The balance of angiogenesis activators and inhibitors in different tissues and their tumors may differ. It is already clear different types of tumor cells use distinct molecular strategies to activate the angiogenic switch. In the mouse models of multistage tumorigenesis, distinct antiangiogenic drugs are effective at different levels during tumorigenesis, ranging from the early onset of angiogenesis to its continuation in end-stage cancer. 20 
